文献速递外周动脉疾病

深静脉动脉化在慢性肢体威胁性缺血医保患者中的结局

Outcomes following deep venous arterialization in Medicare patients with chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2025-04-11

基于美国联邦医疗保险按服务收费理赔数据,2021至2023年共134例慢性肢体威胁性缺血患者接受深静脉动脉化(DVA)。6个月和1年无截肢生存率分别为42%和33%,1年保肢率、免于主要不良肢体事件率和生存率分别为53%、36%和65%。作者指出真实世界无截肢生存率明显差于PROMISE II试验,需进一步研究患者选择标准和DVA临床实用性。

要点

  • 134例CLTI患者接受DVA后,6个月和1年无截肢生存率分别为42%和33%。
  • 1年保肢率53%、免于主要不良肢体事件率36%、生存率65%。
  • 真实世界无截肢生存率明显差于PROMISE II报告的6个月66%。

核心结论

  • 在无传统血运重建选择的患者中,DVA本质上用于高风险个体,这些患者仍面临高截肢和死亡风险。
  • 本分析中无截肢生存率明显差于PROMISE II报告的结果,对DVA在真实世界实践中的普遍适用性提出疑问。
  • 关于DVA的患者选择标准和临床实用性需进一步研究。

研究设计与样本

  • 回顾性队列研究,基于美国联邦医疗保险按服务收费承运人理赔文件,纳入2021年1月1日至2023年12月31日期间接受DVA的按服务收费受益人。
  • 通过现行程序术语代码0620T识别DVA手术,共纳入134例因CLTI接受DVA的患者。
  • 含死亡的终点采用传统Kaplan-Meier法估计累积发生率,非死亡终点采用累积发生率函数并考虑死亡竞争风险。

主要发现

  • 患者中位年龄70岁,男性66%,白人63%,组织缺损72%,高血压99%,高脂血症96%,慢性肾脏病89%,糖尿病83%。
  • DVA术后6个月和1年无截肢生存率分别为42%和33%。
  • 1年保肢率、免于主要不良肢体事件率和生存率分别为53%、36%和65%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite advances in the management of chronic limb-threatening ischemia (CLTI), a large proportion of these patients are not candidates for traditional revascularization and may be destined for major amputation. Given this medically complex and no-option patient population, deep venous arterialization (DVA) has been recently revitalized as a limb salvage technique, whereby an arteriovenous fistula in the lower leg is created to supply more oxygenated blood via the venous system to the foot. Recently, PROMISE II (Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia) demonstrated a 6-month amputation-free survival (AFS) rate of 66% after DVA. With this trial in mind, our study aimed to evaluate the real-world outcomes of this procedure. METHODS: The study population included all patients undergoing a DVA from January 1, 2021, through December 31, 2023 among fee-for-service beneficiaries identified in the Medicare Fee-for-Service Carrier Claims file. DVA procedures were identified using Current Procedural Terminology code 0620T. Outcomes included limb salvage, freedom from major adverse limb events (defined as major amputation or ipsilateral reintervention), survival, and AFS. Cumulative incidences for outcomes that include death were estimated from traditional Kaplan-Meier methods; for non-death end points, outcomes were estimated from the cumulative incidence function, accounting for the competing risk of death. RESULTS: Between 2021 and 2023, 134 patients underwent a DVA for CLTI. Among these, the median age was 70 years and the majority of patients were male (66%), White (63%), and had tissue loss (72%), hypertension (99%), hyperlipidemia (96%), chronic kidney disease (89%), and diabetes (83%). After a DVA for CLTI, the 6-month and 1-year AFS incidences were 42% and 33%, respectively. One-year incidences of limb salvage, freedom from major adverse limb events, and survival were 53%, 36%, and 65%, respectively. CONCLUSIONS: Among patients with no traditional options for revascularization, our data demonstrate that DVA is a procedure that is, by its nature, performed on high-risk individuals who continue to have a high risk of limb loss and mortality. Importantly, AFS in our analysis was notably worse than that reported in PROMISE II and, as such, raises questions about the generalizability of this procedure in real world practice. Further investigation is needed regarding patient selection criteria for and the clinical usefulness of the DVA procedure.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Darling JD, Li S, Lee A, et al. Outcomes following deep venous arterialization in Medicare patients with chronic limb-threatening ischemia. J Vasc Surg. 2025. PMID: 40220975. doi:10.1016/j.jvs.2025.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。